Posted by Michael Wonder on 27 May 2025
ICER releases draft evidence report on treatments for spinal muscular atrophy
27 May 2025 - Public comment period now open until 24 June 2025; requests to make oral comment during public meeting also being accepted.
The ICER today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of apitegromab (Scholar Rock), nusinersen (Spinraza, Biogen), onasemnogene abeparvovec-xioi (Zolgensma, Novartis), and risdiplam (Evrysdi, Genentech) for spinal muscular atrophy.
